Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis

Author: Gross, Volker

Source: Expert Opinion on Pharmacotherapy, Volume 9, Number 7, May 2008 , pp. 1257-1265(9)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Background: Budesonide is a glucocorticoid with high topical glucocorticoid activity and low systemic availability. Oral pH-modified release budesonide has been investigated for the treatment of various inflammatory intestinal diseases. Objective: To summarise the investigational data of oral pH-modified release budesonide for the treatment of Crohn's disease, ulcerative colitis, collagenous colitis and lymphocytic colitis. Methods: Assessment of all published (full paper or meeting abstract) clinical studies with oral pH-modified release budesonide for the treatment of inflammatory intestinal diseases. Results/conclusion: Oral pH-modified release budesonide induces remission in mild-to-moderately active Crohn's disease of the ileum and/or ascending colon. This drug is useful to replace conventional systemic glucocorticoids in patients with ileocoecal Crohn's disease. Open-label studies showed efficacy in ulcerative colitis, but this finding has to be confirmed in controlled trials. Oral pH-modified release budesonide is also effective for the treatment of collagenous colitis and lymphocytic colitis.

Keywords: budesonide; collagenous colitis; Crohn's disease; induction of remission; lymphocytic colitis; maintenance of remission; ulcerative colitis

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656566.9.7.1257

Publication date: 2008-05-01

More about this publication?